- Two Health Consortia to Develop a Detailed Feasibility Proposal for Europe’s Next €1-billion Science Projects
- NICE Develops a Medtech Innovation Briefing on Axumin
- Gustave Roussy and Institut Bergonié, Partners for Early Phase Trials and Therapeutic Innovation in Oncology
- Withdrawal of the EU Marketing Authorisation Applications for Cavoley and Efgratin
- FDA Approved Caplacizumab-yhdp
- eUpdate: Hepatocellular Carcinoma Algorithms
Articles: Melanomas
Lester J Layfield et al.
European Oncology & Haematology, 2014;10(1):58–61
Lester J Layfield et al.
Oncology & Hematology Review, 2014;10(1):21–4
Oncology & Hematology Review 2013;9(1):36–40.
Kenneth F Grossmann et al., Shelley Christiansen et al.
Oncology & Hematology Review 2013;9(2):132–7
Oncology & Hematology Review (US), 2012;8(2):100-5
Breno R Lima et al., Arun D Singh et al.
European Oncology & Haematology, 2012;8(2):101–4
Byron E Wright,MD, FACS et al., Armando E Giuliano, MD, FACS et al.
US Oncological Review, 2008;4(1):11-4
Michael P O’Connell et al., Ashani T Weeraratna et al.
US Oncological Review, 2008;4(1):64-7
Sanjiv S Agarwala et al.
European Oncological Disease, 2007;1(2):100-2
Sonata Saulyte Trakymien et al.
European Oncology & Haematology, 2011;7(1):76-80
Anirban De et al., Winston Rennie et al.
European Oncology, 2009;5(1):35-7
Bryan Burmeister et al.
Asia-Pacific Oncology & Haematology, 2008;1(1):60-2
Joseph J Bennett et al.
US Oncological Disease, 2006;1(1):16-9
Marc S Ernstoff et al.
US Oncology Review, 2005;1(1):1-4